📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Religare Enterprises Q3 FY26 Income Rises to ₹2,067.9 Cr; Care Health AUM Crosses ₹10,000 Cr
Religare Enterprises reported a consolidated total income of ₹2,067.9 crores for Q3 FY26, up from ₹1,670.2 crores in the same quarter last year. Despite revenue growth, the company posted a consolidated loss before tax of ₹103.1 crores, impacted by one-time employee benefit provisions under the new labor code. The insurance subsidiary, Care Health, remains a strong performer with retail business growing 41% and its AUM crossing the ₹10,000 crore milestone. Governance remains a focal point with the proposed induction of Burman family members and Jimeet Modi to the Board.
Key Highlights
Consolidated total income increased to ₹2,067.9 crores in Q3 FY26 vs ₹1,670.2 crores in Q3 FY25.
Care Health Insurance retail premium grew by 41% YoY, with total 9M premium reaching ₹7,906 crores.
Care Health AUM crossed ₹10,000 crores with a solvency ratio of 1.70 as of December 2025.
One-time wage code provisions of ₹13.5 crores impacted quarterly profitability in the insurance segment.
Board expansion proposed to include Dr. Anand Burman, Mohit Burman, Aditya Chand Burman, and Jimeet Modi.
💼 Action for Investors
Investors should monitor the transition in board leadership and the impact of the new management team on long-term strategy. While the consolidated loss is a concern, the robust growth and market share gains in the health insurance subsidiary provide a strong underlying valuation support.
Religare Enterprises Reports Q3 FY26 Net Loss of ₹76.5 Cr; Care Health GWP Grows to ₹7,906 Cr
Religare Enterprises Limited (REL) reported a consolidated net loss of ₹76.5 crore for Q3 FY26, compared to a loss of ₹63.2 crore in the same period last year. While total income grew by 23.8% YoY to ₹2,067.9 crore, rising expenses and higher claims in the insurance segment weighed on profitability. Care Health Insurance remains the primary growth engine, contributing ₹7,906 crore in GWP for 9M FY26 with a 22% market share in the SAHI segment. The company's NBFC arm, Religare Finvest, is now debt-free with over ₹500 crore in cash reserves following successful NPA recoveries.
Key Highlights
Consolidated Total Income increased 23.8% YoY to ₹2,067.9 crore in Q3 FY26.
Care Health Insurance GWP grew to ₹7,906 crore for 9M FY26, up from ₹6,508 crore YoY.
Consolidated Net Loss for 9M FY26 stood at ₹22.5 crore versus a profit of ₹32 crore in 9M FY25.
Care Health's AUM crossed a significant milestone, reaching ₹10,246 crore as of December 2025.
Religare Finvest (NBFC) has resolved legacy issues and maintains a cash balance of ₹500+ crore.
💼 Action for Investors
Investors should focus on the improving operational metrics of Care Health and the debt-free status of the NBFC arm, while remaining cautious about the widening consolidated losses. Monitor the combined ratio in the insurance business, which rose to 111.1% in Q3 FY26, as a key indicator of future profitability.
Religare Enterprises Announces Strategic Demerger of Financial Services; 1:1 Share Swap Ratio
Religare Enterprises (REL) has approved a demerger to separate its financial services and insurance businesses into two independent listed entities. The financial services business, including lending and broking, will be transferred to Religare Finvest Limited (RFL), while REL will retain the insurance business through Care Health Insurance. Shareholders will receive 1 share of RFL for every 1 share held in REL. The demerged undertaking contributed ₹457.29 crore (6.2%) to the consolidated turnover in FY25.
Key Highlights
Demerger of lending, broking, and investment activities into Religare Finvest Limited (RFL)
Shareholders to receive 1 fully paid-up equity share of RFL for every 1 share held in REL
Demerged business accounted for ₹457.29 crore (6.2%) of FY25 consolidated turnover
REL to remain an insurance-focused entity holding the stake in Care Health Insurance Limited
RFL to be listed on BSE and NSE with a target completion date in Q1 FY28
💼 Action for Investors
Investors should maintain their positions to benefit from the value unlocking of two distinct business platforms. Monitor the progress of regulatory approvals from the RBI and NCLT, as these are critical for the Q1 FY28 listing timeline.
Religare Enterprises Announces 1:1 Demerger of Financial Services Business into Religare Finvest
Religare Enterprises (REL) has approved a scheme to demerge its financial services, broking, and investment businesses into its subsidiary, Religare Finvest Limited (RFL). Shareholders will receive one equity share of RFL for every one share held in REL, with RFL set to be listed on both BSE and NSE. The demerged undertaking contributed INR 457.29 Crores, or 6.2% of the total consolidated turnover, in FY25. Post-demerger, REL will focus on its insurance business through Care Health Insurance, while RFL will operate as an independent lending and broking entity.
Key Highlights
Shareholders to receive 1 share of Religare Finvest for every 1 share held in Religare Enterprises.
Demerged financial services division reported a turnover of INR 457.29 Crores (6.2% of total) in FY25.
Religare Enterprises will retain its core investment and shareholding in Care Health Insurance Limited.
Religare Finvest (RFL) is expected to be listed on BSE and NSE by Q1 FY28.
The scheme involves a 100% mirror-image shareholding pattern for the new listed entity.
💼 Action for Investors
Investors should maintain their positions to benefit from the value unlocking of two distinct listed entities. However, note the long implementation timeline with listing expected only by Q1 FY28.
Religare Enterprises Reports Q3 FY26 Standalone Net Loss of ₹11.31 Crore
Religare Enterprises reported a standalone net loss of ₹1,131.19 lakhs for the quarter ended December 31, 2025, a significant increase from the ₹397.38 lakhs loss reported in the previous quarter. Total income for the quarter plummeted to ₹238.61 lakhs from ₹759.58 lakhs in Q2 FY26, largely due to a sharp reduction in 'Other Income'. Expenses rose to ₹1,381.50 lakhs, primarily driven by employee benefit costs which more than doubled to ₹848.95 lakhs. The company continues to face ongoing income tax litigations, as noted by the statutory auditors in their limited review report.
Key Highlights
Standalone net loss widened to ₹11.31 crore in Q3 FY26 compared to a loss of ₹3.97 crore in Q2 FY26.
Total income declined by 68.6% quarter-on-quarter to ₹2.39 crore.
Employee benefit expenses surged to ₹8.49 crore from ₹3.38 crore in the preceding quarter.
The company reported a negative Earnings Per Share (EPS) of ₹0.34 for the quarter.
Auditors included an 'Emphasis of Matter' regarding ongoing income tax litigations and related demands.
💼 Action for Investors
Investors should exercise caution as the standalone entity's losses are widening and operational expenses are rising. The focus should remain on the performance of its underlying subsidiaries in insurance and broking, as well as the resolution of legal and tax contingencies.
Religare Enterprises Clarifies on Care Health Insurance Demerger and Listing Rumors
Religare Enterprises Limited has issued a clarification to the stock exchanges regarding a media report suggesting a potential demerger and listing of Care Health Insurance. The company stated that there is currently no pending information or event that requires disclosure under SEBI (LODR) Regulations. While management acknowledges they evaluate strategic growth opportunities on an ongoing basis, they confirmed that the news item has no material impact at this stage. This response effectively denies any immediate or finalized plans for the rumored demerger.
Key Highlights
Exchange sought clarification on a Moneycontrol article dated February 03, 2026, regarding Care Health Insurance.
Company confirms no event currently exists that requires disclosure under SEBI Regulation 30.
Religare states there is no material impact on the company resulting from the news article.
Management maintains they evaluate strategic opportunities for growth and expansion on an ongoing basis.
The response was filed on February 03, 2026, in response to surveillance queries from BSE and NSE.
💼 Action for Investors
Investors should treat the demerger news as speculative until an official board-approved announcement is made. Monitor the stock for price volatility as the market reacts to the company's denial of immediate plans.
Religare Subsidiary Care Health Insurance Rating Upgraded to IND AA-/ Stable
India Ratings & Research (Ind-Ra) has upgraded the credit rating of Care Health Insurance Limited, a material subsidiary of Religare Enterprises. The rating has been moved to 'IND AA-' with a 'Stable' outlook as of January 29, 2026. This upgrade signifies improved financial strength and operational stability for the subsidiary, which is a key value driver for the parent company. Such a rating improvement typically enhances the subsidiary's ability to attract capital and reflects a robust solvency profile.
Key Highlights
Credit rating of material subsidiary Care Health Insurance upgraded to IND AA-.
Rating outlook assigned as 'Stable' by India Ratings & Research (Ind-Ra).
The rating action was communicated on January 29, 2026, and officially disclosed on January 30, 2026.
Care Health Insurance is a significant contributor to the consolidated performance of Religare Enterprises.
💼 Action for Investors
Investors should view this upgrade as a positive development for Religare's valuation, as its health insurance arm shows strengthening fundamentals. Maintain a positive outlook on the stock while monitoring the subsidiary's growth in the competitive health insurance market.
Religare Subsidiary Care Health Insurance Fined ₹1 Crore by IRDAI
Care Health Insurance Limited (CHIL), a material subsidiary of Religare Enterprises, has been penalized ₹1 crore by the IRDAI for various regulatory violations. The penalty follows an inspection conducted in 2021 which identified breaches in Third Party Administrator (TPA) health services and corporate governance guidelines. In addition to the monetary fine, the regulator issued warnings and advisories regarding financial statement preparation and policyholder interest protection. While the financial impact is limited, the regulatory focus on governance at a key subsidiary is noteworthy for shareholders.
Key Highlights
IRDAI imposed a ₹1 crore penalty on Care Health Insurance Limited (CHIL) for regulatory non-compliance.
Violations relate to TPA Health Services regulations and Corporate Governance guidelines identified during a 2021 inspection.
The regulator also issued formal warnings and advisories concerning financial reporting and policyholder protection.
The penalty is payable by CHIL and will be reflected in the consolidated financial statements of Religare Enterprises.
The order was received on December 15, 2025, following a review of the company's submissions.
💼 Action for Investors
Investors should monitor for any further governance-related disclosures, as repeated regulatory friction can impact the valuation of the insurance subsidiary. The immediate financial impact of ₹1 crore is negligible relative to Religare's overall scale.
Religare Allots 19,85,816 Equity Shares on Warrant Conversion
Religare Enterprises Limited has allotted 19,85,816 equity shares upon conversion of warrants. The face value of each share is ₹10, with a premium of ₹225 each. The allotment was made to promoter entities following the receipt of ₹35,00,00,070, representing 75% of the balance consideration for the warrants. Post-allotment, the issued, subscribed, and paid-up equity share capital of the company increased to ₹3,32,74,04,790, consisting of 33,27,40,479 fully paid-up equity shares.
Key Highlights
Allotment of 19,85,816 equity shares upon warrant conversion.
₹35,00,00,070 received as balance consideration for warrants.
Equity share capital increased to ₹3,32,74,04,790 post allotment.
Each share has a face value of ₹10 with a premium of ₹225.
💼 Action for Investors
Investors should note the increase in equity share capital and monitor the impact of the increased promoter holding on the company's future performance. Review the updated shareholding pattern for changes in promoter influence.